companydata.dkNordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond: Financial statements 2021
CVR: 30197372
Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond (CVR 30197372) has filed annual accounts for 2021. In 2021, the company reported a gross profit of DKK 4,563,506 and a net result of DKK -631,427 compared with DKK -237,815 the year before. That is an increase of 0.9% compared with the year before. Equity amounted to DKK 2,279,349. The solvency ratio was 9.8%. The company had 10 employees in the financial year.
- Gross Profit
- 4,563,506 kr.
- Profit/Loss
- -631,427 kr.
- Equity
- 2,279,349 kr.
- Total Assets
- 23,366,701 kr.
- Employees
- 10
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2021 | - | 4.6 mio. | -631 t. | 2.3 mio. | 10 |
| 2020 | - | 4.5 mio. | -238 t. | 2.9 mio. | 10 |
| 2019 | - | 5.8 mio. | 1.3 mio. | 3.1 mio. | 10 |
Find more companies like Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond
Build lead lists with filters on industry, geography, size and financials — and export straight to Excel.
Try the lead list generatorEvents in 2021
As of November 1, 2021, Trine Jakobi Nøttrup has joined the board of directors of Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond.
As of November 1, 2021, Line Bjørge has joined the board of directors of Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond.
As of November 1, 2021, Suvi-Annika Kristiina Auranen has joined the board of directors of Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond.
As of November 1, 2021, Ane Gerda Zahl Eriksson has joined the board of directors of Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond.
As of November 1, 2021, Henrik Michael Herluf Roed has left the board of directors of Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond.
As of November 1, 2021, Maarit Anita Anttila has left the board of directors of Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond.
As of October 31, 2021, Line Bjørge has left the board of directors of Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond.
As of October 31, 2021, Suvi-Annika Kristiina Auranen has left the board of directors of Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond.
Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond has published its annual report for 2020. Gross profit came to DKK 4,524,460, and the net result was DKK -237,815.
About Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond
Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond is a Danish company of the type Erhvervsdrivende fond based in København Ø, founded in 2006. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Kristine Madsen. The company has 2 employees. In 2025, the company reported a gross profit of DKK 7,463,032 and a net result of DKK -334,181 compared with DKK 1,408,745 the year before. Equity amounted to DKK 4,906,927.